menquadfi
sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - bóluefni - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.
ezetrol tafla 10 mg
n.v. organon* - ezetimibum inn - tafla - 10 mg
ezetimibe alvogen (ezetimibe ratiopharm) tafla 10 mg
alvogen ehf. - ezetimibum inn - tafla - 10 mg
ezetimib medical valley tafla 10 mg
medical valley invest ab - ezetimibum inn - tafla - 10 mg
enrotron flavour (enrotron) tafla 150 mg
animedica gmbh* - enrofloxacinum inn - tafla - 150 mg
enrotron flavour tafla 50 mg
animedica gmbh* - enrofloxacinum inn - tafla - 50 mg
neisvac-c stungulyf, dreifa
pfizer aps - neisseria meningitidis c (oligosakkaríð eða polýsakkaríð) - stungulyf, dreifa
simvastatín alvogen (simvastatín portfarma) filmuhúðuð tafla 20 mg
alvogen ehf. - simvastatinum inn - filmuhúðuð tafla - 20 mg
simvastatín alvogen (simvastatín portfarma) filmuhúðuð tafla 40 mg
alvogen ehf. - simvastatinum inn - filmuhúðuð tafla - 40 mg
varivax stungulyfsstofn og leysir, dreifa
merck sharp & dohme b.v.* - varicella virus oka/merck strain, (live, attenuated) produced in human diploid (mrc-5) cells - stungulyfsstofn og leysir, dreifa